{"id":753,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"thymosin-alpha-1-tests-phase-3-sepsis-trial-2025","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","title":{"rendered":"Thymosin Alpha-1 na sepse: o resultado 2025 TESTS da fase 3"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">O estudo 2025 TESTS \u00e9 mais informativo do que pequenos relat\u00f3rios anteriores de sepse: adultos 1,106 foram randomizados em centros 22, e a timosina alfa-1 n\u00e3o reduziu a mortalidade por todas as causas no dia 28.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Evid\u00eancias em resumo<\/h2><ul class=\"wp-block-list\"><li>O ensaio randomizou adultos 1,106; 1,089 foram inclu\u00eddos na an\u00e1lise modificada de inten\u00e7\u00e3o de tratar.<\/li><li>A mortalidade em vinte e oito dias foi 23.4% com timosina alfa-1 e 24.1% com placebo.<\/li><li>A taxa de risco foi 0.99 (95% CI 0.77 \u2013 1.27; P = 0.93), e nenhum resultado secund\u00e1rio ou de seguran\u00e7a diferiu significativamente.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp\" alt=\"Visualiza\u00e7\u00e3o de dados de testes multic\u00eantricos de sepse em dois bra\u00e7os com resultados quase sobrepostos\" class=\"wp-image-737\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence-300x169.webp 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence-1024x576.webp 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence-768x432.webp 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence-1536x864.webp 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Ilustra\u00e7\u00e3o original da pesquisa editorial. N\u00e3o se trata de figura de estudo, imagem de paciente, fotografia de produto, resultado de ensaio fornecido ou representa\u00e7\u00e3o de lote de cat\u00e1logo.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Registro de estudo<\/h2><p class=\"wp-block-paragraph\">O desfecho prim\u00e1rio foi morte por qualquer causa em 28 dias. A taxa de risco pr\u00f3xima da unidade e o intervalo de confian\u00e7a que cruza um n\u00e3o fornecem evid\u00eancias claras de redu\u00e7\u00e3o da mortalidade na popula\u00e7\u00e3o geral do ensaio.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Projeto<\/strong><span>Fase multic\u00eantrica, duplo-cega, randomizada e controlada por placebo 3<\/span><\/div><div class=\"pim-evidence-row\"><strong>Locais<\/strong><span>Centros 22 na China<\/span><\/div><div class=\"pim-evidence-row\"><strong>ITT modificado<\/strong><span>542 timosina alfa-1; 547 placebo<\/span><\/div><div class=\"pim-evidence-row\"><strong>Mortalidade em dias 28<\/strong><span>23.4% versus 24.1%<\/span><\/div><div class=\"pim-evidence-row\"><strong>Estimativa de efeito<\/strong><span>HR 0.99; 95% CI 0.77\u20131.27; P=0.93<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Resultados no contexto<\/h2><p class=\"wp-block-paragraph\">Intera\u00e7\u00f5es pr\u00e9-especificadas de subgrupos por idade e diabetes geraram poss\u00edveis sinais diferenciais. Os subgrupos s\u00e3o \u00fateis para a elabora\u00e7\u00e3o de estudos futuros, mas n\u00e3o revertem um resultado prim\u00e1rio neutro e n\u00e3o devem ser anunciados como indica\u00e7\u00f5es estabelecidas.<\/p><p class=\"wp-block-paragraph\">Uma meta-an\u00e1lise 2025 reuniu ensaios randomizados 11 com participantes 1,927 e encontrou uma raz\u00e3o de chances geral de 0.73. No entanto, seus subconjuntos multic\u00eantricos e de alta qualidade n\u00e3o foram estatisticamente significativos, e a an\u00e1lise sequencial do ensaio julgou a amostra dispon\u00edvel inadequada. O grande resultado TESTS, portanto, pertence ao centro de qualquer resumo atual.<\/p><h2 class=\"wp-block-heading\">O que a evid\u00eancia n\u00e3o pode estabelecer<\/h2><p class=\"wp-block-paragraph\">Um ensaio nacional pode n\u00e3o representar todos os sistemas de sa\u00fade ou fen\u00f3tipos de sepse.<\/p><p class=\"wp-block-paragraph\">Os efeitos de subgrupo requerem confirma\u00e7\u00e3o e devem continuar a gerar hip\u00f3teses.<\/p><p class=\"wp-block-paragraph\">Um ensaio cl\u00ednico de uma interven\u00e7\u00e3o conclu\u00edda n\u00e3o valida um lote de investiga\u00e7\u00e3o n\u00e3o relacionado.<\/p>","protected":false},"excerpt":{"rendered":"<p>O estudo 2025 TESTS \u00e9 mais informativo do que pequenos relat\u00f3rios anteriores de sepse: adultos 1,106 foram randomizados em centros 22, e a timosina alfa-1 n\u00e3o reduziu a mortalidade por todas as causas no dia 28.<\/p>","protected":false},"author":1,"featured_media":737,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"369","pim_article_type":"Published evidence review","pim_evidence_level":"Large multicenter randomized phase 3 human trial with a neutral primary outcome","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"TESTS phase 3 thymosin alpha-1 sepsis trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39814420\/\",\"note\":\"Primary 2025 multicenter trial; PMID 39814420.\"},{\"title\":\"2025 thymosin alpha-1 sepsis meta-analysis\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40969554\/\",\"note\":\"Eleven RCTs with quality and trial-sequential analyses; PMID 40969554.\"},{\"title\":\"PubChem Thymalfasin record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Thymalfasin\",\"note\":\"Sequence, formula, mass and synonym record; CID 16130571.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result<\/title>\n<meta name=\"description\" content=\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\" \/>\n<meta property=\"og:description\" content=\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"},\"wordCount\":272,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\",\"name\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/thymosin-alpha1-sepsis-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Multicenter two-arm sepsis trial data visualization with near-overlapping outcomes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Thymosin Alpha-1 na sepse: o resultado 2025 TESTS da fase 3","description":"O estudo 2025 TESTS \u00e9 mais informativo do que pequenos relat\u00f3rios de sepse anteriores: adultos 1,106 foram randomizados em centros 22, e a timosina alfa-1 n\u00e3o re\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","og_locale":"pt_BR","og_type":"article","og_title":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result","og_description":"The 2025 TESTS trial is more informative than earlier small sepsis reports: 1,106 adults were randomized across 22 centers, and thymosin alpha-1 did not re\u2026","og_url":"https:\/\/nhdbio.com\/pt-br\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"},"wordCount":272,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","url":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/","name":"Thymosin Alpha-1 na sepse: o resultado 2025 TESTS da fase 3","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"O estudo 2025 TESTS \u00e9 mais informativo do que pequenos relat\u00f3rios de sepse anteriores: adultos 1,106 foram randomizados em centros 22, e a timosina alfa-1 n\u00e3o re\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/thymosin-alpha1-sepsis-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Multicenter two-arm sepsis trial data visualization with near-overlapping outcomes"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/thymosin-alpha-1-tests-phase-3-sepsis-trial-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Thymosin Alpha-1 in Sepsis: The 2025 TESTS Phase 3 Result"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=753"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/753\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/737"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}